These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 9517502)

  • 1. A phase I trial of high dose ProMACE-CytaBOM with granulocyte colony stimulating factor for patients with non-Hodgkin's lymphoma.
    Witzig TE; Camoriano JK; Schroeder G; Kurtin PJ; Habermann TM
    Leuk Lymphoma; 1998 Jan; 28(3-4):307-14. PubMed ID: 9517502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot study on the use of the ProMACE-CytaBOM regimen as a first-line treatment of advanced follicular non-Hodgkin's lymphoma. Gruppo Italiano per lo Studio dei Linfomi.
    Baldini L; Guffanti A; Gobbi P; Colombi M; Federico M; Avanzini P; Cavanna L; Pieresca C; Silingardi V; Maiolo AT
    Cancer; 1997 Mar; 79(6):1234-40. PubMed ID: 9070503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: determination of the maximum-tolerated dose of ProMACE-CytaBOM.
    Gordon LI; Anderson J; Habermann TM; Winter JN; Glick J; Schilder RJ; Cassileth P
    J Clin Oncol; 1996 Apr; 14(4):1275-81. PubMed ID: 8648384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Administration of rhG-CSF increases complete remission rates after CHOP and ProMACE/CytaBOM for non-Hodgkin's lymphoma: a pilot study. Hokkaido Study Group of Malignant Lymphoma and rhG-CSF.
    Okabe M; Maekawa I; Suzuki S; Higuchi M; Morioka M; Nishi K; Itaya T; Ohmura T; Kawamura M; Fuzimoto N
    Leuk Lymphoma; 1995 Nov; 19(5-6):485-91. PubMed ID: 8590851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in chemotherapy for large cell lymphoma.
    Coleman M; Gerstein G; Topilow A; Lebowicz J; Berhardt B; Chiarieri D; Silver RT; Pasmantier MW
    Semin Hematol; 1987 Apr; 24(2 Suppl 1):8-20. PubMed ID: 2438781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
    Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
    N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Southwest oncology group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas.
    Fisher RI; Miller TP; Dana BW; Jones SE; Dahlberg S; Coltman CA
    Semin Hematol; 1987 Apr; 24(2 Suppl 1):21-5. PubMed ID: 2438778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of recombinant granulocyte colony-stimulating factor (G-CSF) in patients treated with ProMACE-CytaBOM for HIV-related non-Hodgkin's lymphoma (NHL).
    Rossi G; Donisi A; Casari S; Re A; Stellini R; Cadeo G; Carosi G
    Haematologica; 1998 Apr; 83(4):317-22. PubMed ID: 9592981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas.
    Fisher RI; Longo DL; DeVita VT; Hubbard SM; Miller TP; Young RC
    Ann Oncol; 1991 Jan; 2 Suppl 1():33-5. PubMed ID: 1710487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
    Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E
    Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II trial of 200% ProMACE-CytaBOM in patients with previously untreated aggressive lymphomas: analysis of response, toxicity, and dose intensity.
    Gordon LI; Young M; Weller E; Habermann TM; Winter JN; Glick J; Ghosh C; Flynn P; Cassileth PA
    Blood; 1999 Nov; 94(10):3307-14. PubMed ID: 10552939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: phase II trial.
    Hainsworth JD; Litchy S; Lamb MR; Rodriguez GI; Scroggin C; Greco FA
    Clin Lymphoma; 2003 Jun; 4(1):36-42. PubMed ID: 12837153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma.
    Stoppa AM; Bouabdallah R; Chabannon C; Novakovitch G; Vey N; Camerlo J; Blaise D; Xerri L; Resbeut M; Di Stefano D; Bardou VJ; Gastaut JA; Maraninchi D
    J Clin Oncol; 1997 May; 15(5):1722-9. PubMed ID: 9164178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CHOP chemotherapy with preemptive granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma: a dose-intensity analysis.
    Jacobson JO; Grossbard M; Shulman LN; Neuberg D
    Clin Lymphoma; 2000 Dec; 1(3):211-7; discussion 218. PubMed ID: 11707832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
    Longo DL; DeVita VT; Duffey PL; Wesley MN; Ihde DC; Hubbard SM; Gilliom M; Jaffe ES; Cossman J; Fisher RI
    J Clin Oncol; 1991 Jan; 9(1):25-38. PubMed ID: 1702144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fourteen-day CHOP supported with granulocyte colony-stimulating factor in patients with aggressive non-Hodgkin's lymphoma: results of a phase II study.
    Gregory SA; Case DC; Bosserman L; Litwak DL; Berry WR; Kalman LA; Belt RJ; Saven A
    Clin Lymphoma; 2003 Sep; 4(2):93-8. PubMed ID: 14556680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study.
    Miller TP; Dahlberg S; Weick JK; Files JC; Eyre HJ; Pendergrass KB; Fisher RI
    J Clin Oncol; 1990 Dec; 8(12):1951-8. PubMed ID: 1700079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
    Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
    Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ProMACE-cytaBOM versus MACOP-B in intermediate and high grade NHL. Preliminary results of a prospective randomized trial.
    Federico M; Moretti G; Gobbi PG; Avanzini P; Cavanna L; Carotenuto M; Lombardo M; Leone G; Pitini V; Abbadessa V
    Leukemia; 1991; 5 Suppl 1():95-101. PubMed ID: 1716340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.
    Gómez H; Mas L; Casanova L; Pen DL; Santillana S; Valdivia S; Otero J; Rodriguez W; Carracedo C; Vallejos C
    J Clin Oncol; 1998 Jul; 16(7):2352-8. PubMed ID: 9667250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.